Clinical

The date a rheumatology-related document, referral, lab result, or prior authorization request was received by the treating facility or specialty practice. Used to track response timelines and measure gaps between ordering and result availability.

An external identifier or pointer linking a rheumatology record to a related document, clinical guideline, prior authorization, or external system entry. Used to cross-reference lab orders, imaging studies, or biologic therapy approvals in autoimmune disease management.

The date a rheumatology condition, symptom, or disease flare was documented as resolved or in remission. Captures the endpoint of active disease episodes for autoimmune conditions such as rheumatoid arthritis, gout, or inflammatory arthritis.

Respiratory rate or pulmonary function measurement recorded during rheumatology encounters. Relevant for monitoring interstitial lung disease, a common comorbidity in autoimmune conditions including rheumatoid arthritis, scleroderma, and myositis.

The documented outcome of a rheumatology diagnostic test, lab panel, imaging study, or clinical assessment. Includes values from anti-nuclear antibody panels, synovial fluid analysis, bone density scans, or disease activity scoring in autoimmune conditions.

Tracks the version or update iteration of a rheumatology treatment plan, diagnosis code assignment, or clinical documentation record. Used to maintain audit history when modifying biologic therapy protocols or autoimmune disease management plans.

A quantified or categorized assessment of a patient's risk level for disease progression, joint damage, cardiovascular complications, or adverse medication effects in autoimmune and musculoskeletal conditions. Informs treatment escalation and monitoring frequency decisions.

The administration pathway for rheumatology medications, including subcutaneous, intravenous, oral, or intra-articular routes. Critical for documenting biologic and DMARD delivery methods such as IV infusions for rituximab or subcutaneous injections for adalimumab.

A composite numerical value derived from validated rheumatology assessment tools such as DAS28, CDAI, RAPID3, or SLEDAI. Quantifies disease activity severity in autoimmune conditions to guide treatment decisions and track patient response to therapy.

The numerical ordering assigned to rheumatology diagnoses, procedures, medication regimens, or treatment steps within a patient record. Used to prioritize primary versus secondary autoimmune conditions and establish the order of therapeutic interventions.

Classifies the seriousness of a rheumatology condition or disease flare on a defined scale such as mild, moderate, or severe. Guides biologic therapy selection, DMARD escalation, and care intensity decisions in autoimmune diseases like rheumatoid arthritis or lupus.

The biological sex classification of a rheumatology patient, recorded to support epidemiological analysis and clinical decision-making. Highly relevant given significant sex-based differences in autoimmune disease prevalence, such as lupus and RA affecting women at much higher rates.

Identifies the originating system, facility, or data feed from which a rheumatology record was received, such as a referring physician, laboratory system, imaging center, or health information exchange. Used for data provenance and reconciliation in autoimmune disease management.

The date marking the beginning of a rheumatology condition, treatment episode, medication regimen, or clinical trial enrollment. Used to calculate disease duration, therapy response timelines, and eligibility windows for biologic or DMARD treatment in autoimmune conditions.

The recorded clock time marking the beginning of a rheumatology clinical encounter, infusion therapy session, or procedure for patients with autoimmune and musculoskeletal conditions such as rheumatoid arthritis, lupus, or gout. Used in scheduling and duration tracking.

The US state or territory associated with a rheumatology clinical encounter, referral, or provider location. Used in geographic reporting, licensure validation, and network adequacy analysis for autoimmune and musculoskeletal specialty care access and claims adjudication.

The current operational or clinical status of a rheumatology encounter, referral, treatment plan, or patient case involving autoimmune or musculoskeletal conditions. Values may include active, pending, closed, or suspended, driving downstream workflow routing and reporting.

The concentration or dosage strength of a medication prescribed or administered within a rheumatology treatment plan, such as methotrexate or biologics for autoimmune conditions. Expressed in units like mg or mg/mL and used in pharmacy dispensing and clinical documentation.

A partial aggregated cost or utilization figure for rheumatology services rendered to patients with autoimmune or musculoskeletal diagnoses, calculated before applying adjustments such as copays, capitation, or bundled payment offsets in claims or financial reporting systems.

The calendar date on which a surgical procedure was performed for a rheumatology patient, such as joint replacement or synovectomy for conditions including rheumatoid arthritis or lupus. Used in episode-of-care tracking, surgical outcomes reporting, and claims adjudication.